Agilent AdvanceBio SEC 200 Å 1.9 μm columns - Fast Separations for Aggregates and Fragments

Significance of the Topic

Size exclusion chromatography is a benchmark technique for monitoring protein aggregate levels in biotherapeutics. Aggregates and low molecular weight fragments are critical quality attributes in monoclonal antibodies and antibody drug conjugates that can affect efficacy, safety, and regulatory compliance. Fast, high resolution separations support both research and quality control by improving sample throughput and analytical confidence.

Objectives and Study Overview

This study evaluates the chromatographic performance of Agilent AdvanceBio SEC 200 Å 1.9 µm columns. The goals are to compare separation efficiency, peak shape, mechanical stability, and reproducibility against two competitive SEC columns under UHPLC and HPLC conditions. Analytical throughput and column lifetime are assessed to determine practical benefits in routine biopharmaceutical workflows.

Methodology

• Analytes: SigmaMAb mixed with defined low molecular weight fragments (LMW1 and LMW2) and Bio-Rad protein standards with uridine challenge.
• Mobile phase: 50 mM sodium phosphate, 200 mM sodium chloride, pH 7.0 for mAb samples; 150 mM sodium phosphate, pH 7.0 for stability tests.
• Flow rates: 0.35 mL/min for comparative resolution experiments; up to 0.7 mL/min for throughput testing.
• Columns: Agilent AdvanceBio SEC 200 Å 1.9 µm columns (4.6×300 mm and 4.6×150 mm), competitor columns with 1.7 µm 200 Å and 2.0 µm 250 Å packing.
• Injection volume: 1–2 µL; detection at UV 220 nm; temperature 25 °C.

Used Instrumentation

• Agilent 1260 Infinity II Bio-inert LC system
• Agilent OpenLab CDS software

Main Results and Discussion

• Resolution: AdvanceBio SEC columns achieved monomer/dimer resolution above 2.5, outperforming competitor columns (around 2.1–2.3), with peak widths reduced by 10–20%
• Inertness: Hydrophilic bonding on 1.9 µm particles minimized secondary interactions, yielding sharper peaks and consistent elution profiles even for sticky ADC samples. Competitor columns showed delayed elution and peak tailing.
• Mechanical stability: After 400 stop/start injection cycles, plate count loss stayed below 2%, demonstrating robust column lifetime and consistent efficiency maintenance.
• Throughput: Using a 150 mm AdvanceBio SEC column at 0.7 mL/min, up to 480 injections per 24 hours were possible without loss of resolution, doubling sample processing capacity compared to older column technologies.
• Reproducibility: QC overlay of 400 injections at 50-injection intervals showed retention time RSD below 3% and resolution precision under 3.5%, confirming reliable batch-to-batch performance.

Benefits and Practical Applications

• High resolution separations accelerate aggregate and fragment profiling in biopharmaceutical development and QC
• Fast cycle times and extended column lifetime reduce per-sample costs and instrument idle time
• Inert column surface improves data quality for sensitive ADC and monoclonal antibody analyses
• Reliable reproducibility supports stringent regulatory requirements for biologics characterization

Future Trends and Potential Applications

• Integration with mass spectrometry for detailed aggregate structure elucidation
• Miniaturization and microflow SEC formats for limited sample volume applications
• Advanced column chemistries targeting specific aggregate types or post-translational modifications
• Automation of SEC-based workflows within high throughput screening platforms

Conclusion

Agilent AdvanceBio SEC 200 Å 1.9 µm columns deliver superior resolution, speed, and durability for protein aggregate and fragment analysis. Their inert surface chemistry and robust mechanical stability provide high confidence in routine biopharmaceutical QC and research applications, enabling significant productivity gains and cost savings.